Peter H. Reinisch

Global Life Science Ventures AG (GLSV-Switzerland) is the Swiss office of the independent venture capital firm which was founded in 1996 with the support of Dr. Stefan Engelhorn. One of the first European venture capital firms to focus exclusively on the life science industry, GLSV-Switzerland advises and manages funds for leading European banks, insurance companies, funds-of-funds and family offices. In addition to their office in Zug, the firm has an office in Munich, Germany. The two offices act as one team with a global perspective, concentrating on their German-speaking home markets and pursuing international partnering opportunities, including investments in the US. GLSV-Switzerland is sensitive to investing in companies with technological or bioethical issues which are still the object of public debate and advises potential investee companies to adhere to core ethical values published in official publications.

Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.